GlassScriptPhysician profile
Beth Gingrich Deckard
NPI 1619916111
$5,985.27
in general payments reported to CMS, 2019-2025
41 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,589 · 2022: $1,112 · 2023: $1,279 · 2024: $1,494 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,229.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $628.50 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $522.51 | 2021-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Abbvie INC. | $460.04 | 2021-2025 | |
| Amgen INC. | $325.64 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $295.65 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.03 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $282.50 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $202.76 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $193.97 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $176.26 | 2021-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $129.27 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.11 | 2022-2023 | Xifaxan |
| Abbott Laboratories | $99.83 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $91.45 | 2024-2025 | Voquezna |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Deckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.